Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sticking Point: Novartis Menveo Vaccine Faces Delay Over FDA Request For Info

This article was originally published in The Pink Sheet Daily

Executive Summary

Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.

You may also be interested in...



One More Shot? The ACIP Continues Its Review Of Meningitis Vaccines

When the CDC's Advisory Committee on Immunization Practices meets in Atlanta on Feb. 25, the working group will edge closer to making a difficult decision - whether a trio of vaccines to treat meningitis eventually should be recommended routinely for infants and toddlers less than two years of age

One More Shot? The ACIP Continues Its Review Of Meningitis Vaccines

When the CDC's Advisory Committee on Immunization Practices meets in Atlanta on Feb. 25, the working group will edge closer to making a difficult decision - whether a trio of vaccines to treat meningitis eventually should be recommended routinely for infants and toddlers less than two years of age

Novartis Needs A Bigger Safety Database For Menveo, FDA Says

Review of application for ages 11 and up proceeds, but the agency wants to see more data on infants, pushing a second filing for the meningitis vaccine to 2011 in the U.S.

Topics

UsernamePublicRestriction

Register

PS069675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel